Your browser doesn't support javascript.
loading
Graves' Disease after Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in a Type 1 Diabetes Patient.
Sakai, Mayu; Takao, Ken; Kato, Takehiro; Ito, Kodai; Kubota, Sodai; Hirose, Tokuyuki; Liu, Yanyan; Mizuno, Masami; Hirota, Takuo; Suwa, Tetsuya; Horikawa, Yukio; Yabe, Daisuke.
Afiliação
  • Sakai M; Department of Diabetes, Endocrinology and Metabolism, Gifu University Graduate School of Medicine, Japan.
  • Takao K; Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Japan.
  • Kato T; Department of Diabetes, Endocrinology and Metabolism, Gifu University Graduate School of Medicine, Japan.
  • Ito K; Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Japan.
  • Kubota S; Department of Diabetes, Endocrinology and Metabolism, Gifu University Graduate School of Medicine, Japan.
  • Hirose T; Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Japan.
  • Liu Y; Department of Diabetes, Endocrinology and Metabolism, Gifu University Graduate School of Medicine, Japan.
  • Mizuno M; Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Japan.
  • Hirota T; Department of Diabetes, Endocrinology and Metabolism, Gifu University Graduate School of Medicine, Japan.
  • Suwa T; Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Japan.
  • Horikawa Y; Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Japan.
  • Yabe D; Department of Diabetes, Endocrinology and Metabolism, Gifu University Graduate School of Medicine, Japan.
Intern Med ; 61(10): 1561-1565, 2022.
Article em En | MEDLINE | ID: mdl-35569928
ABSTRACT
Although there is a great demand for increased coronavirus disease 2019 (COVID-19) vaccination worldwide, rare side effects of the vaccine in susceptible individuals are attracting attention. We recently treated a patient with type 1 diabetes who had HLA-A*240201/A*020101, B*5401/B*5601, DRB1*0405/DRB1*0405, DPB1*0501/DPB1*0501 and DQB1*0401/DQB1*040 and developed Graves' disease soon after the administration of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. While causal relationships between vaccinations and adverse events are difficult to discern due to both confounding and masking factors, our findings suggest that attention to possible adjuvant-related endocrinological diseases in certain individuals receiving SARS-CoV-2 vaccines is appropriate.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Graves / Diabetes Mellitus Tipo 1 / COVID-19 Limite: Humans Idioma: En Revista: Intern Med Assunto da revista: MEDICINA INTERNA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Graves / Diabetes Mellitus Tipo 1 / COVID-19 Limite: Humans Idioma: En Revista: Intern Med Assunto da revista: MEDICINA INTERNA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão